Potential Of Live Recombinant 'Bakers Yeast' As Antigen Delivery Vectors : Application In Generating Antibodies To GFP And Envelope Protein Of JEV by Upadhyaya, Bhaskar
Vaccination against disease causing pathogens is the most cost e f f e c w  
practiced public health intervention. Majority of the vaccines in use today are prepared from 
either live attenuated or killed organisms. Although successful in eradicating or drasticallj 
decreasing the incidence and morbidity associated with a large number of infectious diseases 
such as smallpox, polio and diphtheria, the current procedures for vaccine preparation suffer 
from crucial drawbacks. These include the inability to prepare large amount of material, 
safety of vaccines and personnel involved in vaccine preparation, possible reactogenicity of 
the vaccine preparation due to its inadequate attenuation or inactivation and the fear of their 
reversion to virulent form. Apart fiom these considerations, the mass distribution and 
immunization of several vaccines are often limited by their high production cost. These 
concerns have prompted the testing of various approaches, majority of which focus on the 
development of subunit vaccines. Antigens considered for subunit vaccine development are 
usually purified fiom a range of expression systems which include bacterial, yeast. 
baculovirus and mammalian expression systems. 
The idea that recombinant antigen expressing yeast cells could themselves serve as 
antigen delivery vectors and induce immune response to the recombinant protein has been 
less explored. The fact that Saccharomyces cerevisiae has a 'generally regarded as safe 
status' (GUS) ,  is not normally recognized as a pathogen and can be easily cultured, make5 
it3 #ucriti;rble organism for the development of cost effective and safe subunit vaccines. Use ol 
whole recombinant yeast as an antigen delivery vector avoids the tedious preparation oj 
purified protein antigen and the use of adjuvant for effective immune response generation a 
Saccharomyces cerevisiae itself serves as an acijuvant [1,2]. However, despite these 
advantages, so far only two groups have reported the use of whole recombinan 
Saccharomyces cerevisiae yeast to generate immune responses. The first report by Schreudei 
et al. [3] showed weak antibody responses to Hepatitis I3 virus surface antigen (HBsAg) ir 
mice immunized with heat killed recombinant Siaccha~"umyces cerevisiae yeast expressing 
HlBsAg on the surface. In the second report [4], T cell responses to OVA and HlV-1 antigem 
were demonstrated in mice immunized with h o l e  live m m b b t  yeast expressing eitb 
OVA or HIV-gplm protein. 
In this study, we have re-investigated the potentid of whole m m b ' m i  
Saccharomyces cerevisiae to generaie antibody reqxma to lx&mZogcm 8ntigens. ia Qkac 
previous report [3], s d a c e  antigen expression was adopted to ensure that the antigen am lx 
directly recognized by the B cells. We initially e x p l d  the f ~ i b ' i t y  of ';thsis w b k  


immunized into mice and sera collected after booster doses were screened for the presence of 
anti-E antibody response. As before, we observed good anti-E antibody response in mice 
immunized with these E protein sub-fragments. However, sera collected from mice 
immunized with yeast expressing the various E protein sub-fragments failed to neutralize 
JEV and these mice were not protected from lethal JEV challenge. 
The lack of generation of neutralizing antibodies and absence of protection observed 
above could be either due to the inability of the neutralizing epitope to be recognized by B 
cells or the inability of the E sub-fragments expressed on the yeast cell surface to attain the 
right conformation to generate neutralizing antibodies. It is also possible, that the neutralizing 
epitopes are lost due to partial proteolysis of the E protein sub-fragments by yeast secretory 
pathway prclteases during their transit to the cell suface. We have not investigated these 
possibilitie3"'in detail but have carried out an indirect analysis by neutralization assays to 
check for the presence or absence of neutralizing epitopes in the aa238-398 and the 
aa373-399 E protein sub-fragments. This analysis suggests that these fragments may not have 
been correctly folded to generate neukalizing antibodies and hence no protection was 
observed in mice immunized with yeast expressing these E sub-fragments. 
Our study demonstrates the efficacy of whole live yeast expressing heterologous 
antigens on its cell surface in generating a good antibody response to the surface expressed 
foreign protein. However, to generate immunity to JEV using this immunization method, 
modifications at the level of protein and in the yeast surface expression strategy may be 
necessary to achieve neutralizing antibody production. Since we have observed good 
antibody responses to several antigens that we have tried, this immunization ap- 
be extended to other therapeutically relevant antigens. 
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